Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Oxytocin for Prevention of Opioid-Induced Postoperative Sleep Apnea in Bariatric Surgery
NCT07902752Phase 2Not yet recruiting
- Sponsor
- George Washington University
- Start
- May 2027
- Primary completion
- Jul 2029
01
Overview
Phase 2, randomised, double-blind trial of oxytocin nasal spray in opioid-induced respiratory depression (OIRD) (2 arms), sponsored by George Washington University. Primary endpoints: Postoperative Hypopnea Events at 2.5 hours, Postoperative Apnea Events at 2.5 hours and 1 more. Planned start May 2027; status: not yet recruiting.
02
Drugs
oxytocin nasal spray
03
Conditions
opioid-induced respiratory depression (OIRD)
Beyond the preview
Go deeper on NCT07902752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07902752.